Oxford Pharmascience Group

Oxford Pharmascience is a drug development company that re-develops approved drugs using proprietary formulation technologies to make them better, safer and easier to take. Since Oxford Pharmascience's products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market. The Company's pipeline is focused on cardiovascular disease and pain relief indications addressing unmet patient needs with significant commercial potential in global markets. The company was founded in February'08 and floated in London's AIM market in February 2010.
London, GB
10 (est)-9%

Oxford Pharmascience Group Locations

London, GB

Oxford Pharmascience Group Metrics

Oxford Pharmascience Group Summary

Founding Date


Market capitalization

$253 B

Closing share price


Oxford Pharmascience Group Financials

FY, 2013FY, 2014FY, 2015


£1.03 M£705 K£749 K

Revenue growth, %


Gross profit

£336 K£223 K£158 K

Gross profit Margin, %


Operating expense total

£1.89 M£3.72 M£4.13 M

Oxford Pharmascience Group News

Oxford Pharmascience Group Company Life